5 Best Construction Material Stocks To Own For 2014

Microsoft's (NASDAQ: MSFT  ) expensive investment and Nokia's (NYSE: NOK  ) risky gamble appear to be paying off.

Kantar is out with its smartphone domestic market share report for the second quarter, and after conducting more than 240,000 interviews in this country, it appears as if Windows Phone is gaining ground as a mobile operating system.

Hold your applause.

We're only talking about Windows going from 2.9% a year ago to 4% today. This remains a country where Google's (NASDAQ: GOOG  ) Android and Apple's (NASDAQ: AAPL  ) iPhone command a whopping 94% of the market.

In fact, Microsoft's growth hasn't really come at the expense of Google or Apple. They combined for just 91.8% in market share a year ago, so clearly the two market leaders are even more popular today. Microsoft's growing at the expense of BlackBerry (NASDAQ: BBRY  ) , which has seen its stateside market share shrink from 4% to 1.1% over the past year.

Top 5 Gold Stocks To Watch Right Now: Eagle Materials Inc (EXP)

Eagle Materials Inc., incorporated on January 27, 1994, manufactures and distributes gypsum wallboard and also manufactures and sells cement. Gypsum wallboard is distributed throughout the United States with particular emphasis in the geographic markets nearest to its production facilities. The Company sells cement in six regional markets, including northern Nevada and California, the greater Chicago area, the Rocky Mountain region, the Central Plains region and Texas. Its gypsum wallboard business is supported by its recycled paperboard business, while its cement business is supported by its concrete and aggregates business. The Company operates in Cement and Concrete and Aggregates, and Gypsum Wallboard and Recycled Paperboard segments. As of March 31, 2013, the Company operated six cement plants (one of which belongs to its joint venture company), five gypsum wallboard plants, one recycled paperboard plant, seventeen concrete batching plants and four aggregates facilities. The Company�� products are used in the construction and renovation of houses, roads, bridges, commercial and industrial buildings and other, newer generation structures like wind farms.

Cement, Concrete and Aggregates Operations

The Company�� cement production facilities are located in or near Buda, Texas; LaSalle, Illinois; Laramie, Wyoming; Sugar Creek, Missouri; Tulsa, Oklahoma and Fernley, Nevada. The Company�� cement subsidiaries are wholly-owned except the Buda, Texas plant, which is owned by Texas Lehigh Cement Company LP, a limited partnership joint venture owned 50% by the Company and 50% by Lehigh Cement Company LLC, a subsidiary of Heidelberg Cement AG. Its LaSalle, Illinois plant operates under the name of Illinois Cement Company; the Laramie, Wyoming plant operates under the name of Mountain Cement Company; the Fernley, Nevada plant operates under the name of Nevada Cement Company and its Sugar Creek, Missouri and Tulsa, Oklahoma plants operate under the name Central Plains Cement Com! pany. The Company produces and distributes ready-mix concrete from Company-owned sites north of Sacramento, California; Austin, Texas and the greater Kansas City area. The Company�� activities in its frac sand business are in the Utica, Illinois area and in south Texas. The Company sells aggregates to building contractors and other customers engaged in a variety of construction activities.

Gypsum Wallboard and Recycled Paperboard Operations

The Company owns five gypsum wallboard manufacturing facilities. As of March 31, 2013, the Company�� gypsum wallboard production totaled 1,950 million square feet. Total gypsum wallboard sales were 1,909 million square feet during the fiscal year ended March 31, 2013 (fiscal 2013). The Company also manufactures alternative products, including containerboard grades (such as linerboard and medium) and lightweight packaging grades (such as bag liner). In addition, recycled industrial paperboard grades (tube/core stock and protective angle board stock) are produced to maximize manufacturing efficiencies. The Company�� manufactured recycled paperboard products are sold to gypsum wallboard manufacturers and other industrial users.

The Company competes with USG Corporation, National Gypsum Company and Koch Industries.

Advisors' Opinion:

• [By Rich Duprey]

  Cement and building materials maker�Eagle Materials� (NYSE: EXP  ) �announced yesterday�its second-quarter dividend of $0.10 per share, the same rate it's paid since 2008.

5 Best Construction Material Stocks To Own For 2014: Texas Industries Inc (TXI)

Texas Industries, Inc., incorporated on April 19, 1951, is a supplier of construction materials in the southwestern United States. The Company operates in three segments: cement, aggregates and consumer products. Its cement segment produces gray portland cement and specialty cements. The Company�� cement production and distribution facilities are concentrated primarily in Texas and California. Its aggregates segment produces natural aggregates, including sand, gravel and crushed limestone. The Company�� consumer products segment produces ready-mix concrete. It is also a supplier of natural aggregates and ready-mix concrete in Texas and northern Louisiana and in Oklahoma and Arkansas. As of May 31, 2013, the Company had 123 manufacturing facilities in five states.

Cement Segment

The Company produces specialty cements, such as masonry and oil well cements. Its cement production facilities are located at Midlothian, Texas, south of Dallas/Fort Worth, Hunter, Texas, between Austin and San Antonio, and Oro Grande, California, near Los Angeles. It also operates a cement terminal and packaging facility at its Crestmore plant near Riverside, California, and the Company operates its gray portland cement grinding facility on an as needed basis. During the fiscal year ended May 31, 2013 (fiscal 2013), it produced approximately 4.3 million tons of finished cement. The Company shipped approximately 4.4 million tons during fiscal 2013, of which 3.8 million tons were shipped to outside trade customers.

Aggregates Segment

The Company�� operations are conducted from facilities primarily serving the Dallas/Fort Worth and Austin areas in Texas; the southern Oklahoma area, and the Alexandria and Monroe areas in Louisiana. The Company produced approximately 14.2 million tons of natural aggregates during fiscal 2013. It shipped approximately 14.8 million tons of natural aggregates during fiscal 2013, of which 11.3 million tons were shipped to outside trade customers! . The Company shipped approximately 1.0 million cubic yards of lightweight aggregates during fiscal 2013, of which approximately 0.9 million cubic yards were shipped to outside trade customers.

Consumer Products Segment

The Company�� ready-mix concrete operations are situated in three areas in Texas (the Dallas/Fort Worth/Denton area of north Texas, the Austin area of central Texas and from Beaumont to Texarkana in east Texas), in north and central Louisiana, and in southwestern Arkansas. It is also a 40% partner in a joint venture that has ready mix concrete operations in the northern part of central Texas area centered around Waco, Texas. It shipped approximately 2.8 million cubic yards of ready-mix concrete during fiscal 2013. The Company manufacture and supply a substantial amount of the cement and aggregates raw materials used by our ready-mix plants. The Company also marketed its Maximizer packaged concrete mixes in southern California.

Advisors' Opinion:

• [By Holly LaFon]

  Competitively advantaged holdings continued to demonstrate the value of moats at FedEx (FDX), Melco, and Texas Industries (TXI). These holdings were among our largest contributors to performance, and they exemplify activity prevalent across most of our holdings throughout the year.

• [By Monica Gerson]

  Analysts expect Texas Industries (NYSE: TXI) to post its Q1 earnings at $0.01 per share on revenue of $233.63 million. Texas Industries shares gained 1.82% to close at $67.52 yesterday.

5 Best Construction Material Stocks To Own For 2014: CEMEX SAB de CV (CX)

CEMEX, S.A.B. de C.V. (CEMEX), incorporated on January 20, 1931, is a global cement manufacturer with operations in North America, Europe, South America, Central America, the Caribbean, Africa, the Middle East and Asia. The Company is a holding company engaged through the operating subsidiaries in the production, distribution, marketing and sale of cement, ready-mix concrete, aggregates and clinker. As of December 31, 2009, the Company�� cement production facilities were located in Mexico, the United States, Spain, the United Kingdom, Germany, Poland, Croatia, Latvia, Colombia, Costa Rica, the Dominican Republic, Panama, Nicaragua, Puerto Rico, Egypt, the Philippines and Thailand.

The Company manufactures cement through a closely controlled chemical process, which begins with the mining and crushing of limestone and clay, and, in some instances, other raw materials. The clay and limestone are then pre-homogenized, a process which consists of combining different types of clay and limestone. The mix is typically dried, then fed into a grinder, which grinds the various materials in preparation for the kiln. The raw materials are calcined, or processed, at a very high temperature in a kiln, to produce clinker. Clinker is the intermediate product used in the manufacture of cement.

Ready-mix concrete is a combination of cement, fine and coarse aggregates, admixtures (which control properties of the concrete including plasticity, pumpability, freeze-thaw resistance, strength and setting time), and water. The Company is a supplier of aggregates primarily the crushed stone, sand and gravel, used in virtually all forms of construction.

Mexican Operations

During the year ended December 31, 2009, the Mexican operations represented approximately 21% of the Company�� net sales. CEMEX Mexico is a direct subsidiary of CEMEX and is both a holding company for some of the operating companies in Mexico and an operating company involved in the manufacturing and ma! rketing of cement, plaster, gypsum, groundstone and other construction materials and cement by-products in Mexico. CEMEX Mexico, indirectly, is also the holding company for the international operations. The Company owns Tolteca, Monterrey, Maya, Anahuac, Campana, Gallo, and Centenario brands in Mexico. As of December 31, 2009, the Company owned 100% of CEMEX Mexico.

The Company competes with Holcim Ltd., Sociedad Cooperativa Cruz Azul, Cementos Moctezuma, Grupo Cementos Chihuahua and Lafarge Cementos in Mexico.

U.S. Operations

As of December 31, 2009, the Company�� operations in the United States represented approximately 19% of the Company�� net sales. As of December 31, 2009, the Company held 100% of CEMEX, Inc. As of December 31, 2009, CEMEX had a cement manufacturing capacity of approximately 17.9 million tons per year in the United States operations. As of December 31, 2009, the Company operated 14 cement plants located in Alabama, California, Colorado, Florida, Georgia, Kentucky, Ohio, Pennsylvania, Tennessee and Texas. As of December 31, 2009, it also had 48 rails or water served active cement distribution terminals in the United States. As of December 31, 2009, the Company had 336 ready-mix concrete plants located in the Carolinas, Florida, Georgia, Texas, New Mexico, Nevada, Arizona, California, Oregon and Washington and aggregates facilities in North Carolina, South Carolina, Arizona, California, Florida, Georgia, Kentucky, New Mexico, Nevada, Oregon, Texas, and Washington.

Spanish Operations

As of December 31, 2009, the operations in Spain represented approximately 5% of the Company�� net sales. As of December 31, 2009, the Company held approximately 99.8% of CEMEX Espana, the main operating subsidiary in Spain. The cement activities in Spain are conducted by CEMEX Espana. The ready-mix concrete activities in Spain are conducted by Hormicemex, S.A., a subsidiary of CEMEX Espana, and the aggregates activities in Spain ar! e conduct! ed by Aricemex S.A., also a subsidiary of CEMEX Espana.

U.K. Operations

As of December 31, 2009, the Company�� operations in the United Kingdom represented approximately 8% of the Company�� net sales. As of December 31, 2009, it held 100% of CEMEX Investments Limited, the holding subsidiary in the United Kingdom. The Company is a provider of building materials in the United Kingdom with vertically integrated cement, ready-mix concrete, aggregates and asphalt operations. It is also a provider of concrete and precast materials solutions, such as concrete blocks, concrete block paving, roof tiles, flooring systems and sleepers for rail infrastructure.

The Company competes with Lafarge, Heidelberg, Tarmac, and Aggregate Industries in the United Kingdom.

German Operations

As of December 31, 2009, the operations in the Rest of Europe consisted of the operations in Germany, France, Ireland, Poland, Croatia, the Czech Republic, Latvia, Austria and Hungary, as well as the other European assets. The Company is a provider of building materials in Germany, with vertically integrated cement, ready-mix concrete, aggregates and concrete products operations (consisting mainly of prefabricated concrete ceilings and walls). It maintains a network for ready-mix concrete and aggregates in Germany. As of December 31, 2009, the Company held 100% of CEMEX Deutschland AG, the holding subsidiary in Germany.

The Company competes with Heidelberg, Dyckerhoff, Lafarge, Holcim and Schwenk in Germany.

French Operations

As of December 31, 2009, the Company held 100% of CEMEX France Gestion (S.A.S.), the holding subsidiary in France. It is a ready-mix concrete producer and aggregate producer in France. As of December 31, 2009, the Company operated 239 ready-mix concrete plants in France, one maritime cement terminal located in LeHavre, on the northern coast of France, 20 land distribution centers and 42 aggregates quarries.

The Company competes with Lafarge, Holcim, Italcementi, Vicat, Lafarge, Italcementi, Colas (Bouygues) and Eurovia (Vinci) in France.

Irish Operations

As of December 31, 2009, the Company held approximately 61.2% of Readymix Plc, the operating subsidiary in the Republic of Ireland. The operations in Ireland produce and supply sand, stone and gravel, as well as ready-mix concrete, mortar and concrete blocks. As of December 31, 2009, we operated 43 ready-mix concrete plants, 27 aggregates quarries and 15 block plants located in the Republic of Ireland, Northern Ireland and the Isle of Man. The Company imports and distributes cement in the Isle of Man.

The Company competes with CRH, the Lagan Group and Kilsaran in the Republic of Ireland.

Polish Operations

As of December 31, 2009, the Company held 100% of CEMEX Polska Sp. z.o.o. (CEMEX Polska), the holding subsidiary in Poland. It is a provider of building materials in Poland serving the cement, ready-mix concrete and aggregates markets. As of December 31, 2009, CEMEX operated two cement plants and one grinding mill in Poland, with a total installed cement capacity of three million tons per year. As of December 31, 2009, the Company also operated 39 ready-mix concrete plants and nine aggregates quarries in Poland. As of December 31, 2009, the Company also operated 10 land distribution centers and two maritime terminals in Poland.

The Company competes with Heidelberg, Lafarge, CRH and Dyckerhoff in Poland.

Southeast European Operations

As of December 31, 2009, the Company held 100% of CEMEX Hrvatska d.d. (Hrvatska), the operating subsidiary in Croatia. As of December 31, 2009, it operated three cement plants in Croatia, with an installed capacity of 2.4 million tons per year. As of December 31, 2009, the Company also operated ten land distribution centers, three maritime cement terminals, eight ready-mix concrete facilities and one aggregates quarry! in Croat! ia, Bosnia and Herzegovina, Slovenia, Serbia and Montenegro.

Advisors' Opinion:

• [By GuruFocus]

  George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated

• [By Ben Levisohn]

  Shares of Vulcan have gained 7.6%, and given a lift to other cement makers today, including Martin Marietta Materials (MLM), which has risen 4.9% and reports earnings on Thursday, Cemex (CX), which has advanced 1.5%, and Texas Industries (TXI), which is up 4.9%.

• [By Dan Caplinger]

  Even now, though, it's far from clear whether the recent rebound has staying power. Earlier this month, peer Vulcan Materials (NYSE: VMC  ) reported 5% lower shipments of aggregates, although rising prices helped offset the impact, and the company noted double-digit-percentage increases in shipments to hot housing areas including Arizona, California, and Florida. Similarly, Cemex (NYSE: CX  ) posted a substantial loss for its March quarter on with 5% lower revenue, but the Mexican company pointed to strength in the U.S. and Asian markets as offsetting weakness in Mexico, Europe, and Latin America.

• [By Monica Wolfe]

  Cemex SAB de CV (CX)

  As of the close of the third quarter there were nine guru owners of Cemex. These gurus held a combined weighting of 5.30%. During the third quarter, there were three gurus making buys and nine making sells of their stake in CX.

5 Best Construction Material Stocks To Own For 2014: Boral Ltd (BLD)

Boral Limited (Boral), is engaged in the manufacture and supply of building and construction materials in Australia, the United States and Asia. The Company�� operating segments include Construction Materials & Cement, Building Products, Boral Gypsum, and Boral USA. The Construction Materials & Cement is engaged in quarries, concrete, asphalt, transport, landfill, property, cement and concrete placing. The Building Products segment is engaged in Australian bricks, roof tiles, masonry, timber products and windows. The Boral Gypsum involves Australian and Asian plasterboard. The Boral USA is engaged in Bricks, cultured stone, roof tiles, fly ash, concrete and quarries. Advisors' Opinion:

• [By Eric Lam]

  Ballard Power (BLD), which designs and manufactures hydrogen fuel cells, slumped 15 percent to C$1.42, the biggest decline since March. The company yesterday said it will sell about 9 million units at $1.40 a unit for proceeds of about $12.6 million. The cash generated will be used to fund working capital, support growth and general corporate purposes, the company said.

Hot Financial Stocks To Watch Right Now

When markets reach highs and beat records, investing conversations start to talk about the "dumb money." The�dumb money�is not my term, by the way; it's how Wall Street refers to individual investors who repeatedly sell stocks at a low price, only to turn around later and buy them for high prices.

If the mistake is so frequent that it actually has a name, why do we keep doing it, and what can we do to stop?

When we make financial decisions we're faced with a choice: Do we act based on what we know or how we feel?

In an intellectual exercise, knowledge wins. But in the real world, we're hardwired to pursue the things that give us pleasure or provide security and run as fast as possible from the things that cause us pain. This genetic trait means that we're often driven by how we feel instead of what we know.

Here is an example. In December 2008, The Economist published one of its classic covers. I remember seeing this cover, and a year or so later being struck by how well the image captured how I had felt. In fact, when I saw it again I had an emotional response that surprised me as I thought back to those feelings. The picture made me feel like everyone else did during that time. I was depressed, sad, hopeless, and felt like I was a fool for not gathering what little gold I had left before it too fell into the dark, bottomless hole pictured on the cover.

10 Best Dividend Stocks To Own Right Now: Evercore Partners Inc(EVR)

Evercore Partners Inc. operates as an independent investment banking advisory firm. The company operates through two segments, Investment Banking and Investment Management. The Investment Banking segment offers advisory services on mergers, acquisitions, divestitures, and other strategic corporate transactions primarily for multinational corporations and private equity firms; and restructuring advice to companies in financial transition, as well as to creditors, shareholders, and potential acquirers. This segment also provides capital markets advice; underwrites securities offerings; raises funds for financial sponsors; and offers equity research and agency-only equity securities trading for institutional investors. The Investment Management segment manages financial assets for institutional investors; provides independent fiduciary services to corporate employee benefit plans; provides wealth management services for high net-worth individuals; manages private equity funds ; and offers specialized investment management and trustee services. The company operates primarily in the United States, Europe, and Latin America. Evercore Partners Inc. was founded in 1996 and is headquartered in New York, New York.

Advisors' Opinion:

• [By David Hanson and Matt Koppenheffer]

  In this special "Best and Worst 2013" edition of The Motley Fool's everything-financials show, Where the Money Is, banking analysts David Hanson and Matt Koppenheffer tell viewers why Evercore Partners (NYSE: EVR  ) crushed the market in 2013. Despite the increase in its valuation multiple, David thinks the small investment bank could be poised to continue producing strong returns.

Hot Financial Stocks To Watch Right Now: Aviva plc (AV)

Aviva plc provides insurance, savings, and fund management products and services worldwide. It offers life insurance and savings products, which comprise pensions products, such as personal and group pensions, stakeholder pensions, and income drawdown; annuities; protection products, including term assurance, mortgage life insurance, flexible whole life, and critical illness cover; bonds and savings comprising single premium investment bonds, regular premium savings plans, mortgage endowment products, and funding agreements; and investment products consisting of unit trusts, individual savings accounts, and open ended investment companies, as well as equity release and structured settlements. The company also provides general and health insurance products that include personal lines of insurance products, such as motor, household, travel, and creditor insurance; commercial lines of insurance products consisting of fleet, liability, and commercial property insurance; health insurance products comprising private health, income protection, personal accident, and corporate healthcare insurance products; and insurance for corporate and specialty risks. In addition, it offers fund management products and services for institutional, pension fund, and retail clients. Aviva plc sells its products through various distribution channels, including direct sales forces, intermediaries, corporate partnerships, bancassurance, and joint ventures, as well as through the telephone and Internet. The company was formerly known as CGNU plc and changed its name to Aviva plc in July 2002. Aviva plc is headquartered in London, the United Kingdom.

Advisors' Opinion:

• [By Rupert Hargreaves]

  Unfortunately, Prudential only offers a dividend yield of 2.4% at present, below that of its peers, such as Aviva (AV) and Legal & General (LGEN). Moreover, city analysts only expect Prudential to increase its payout by 10% this year and 5% during 2014.

• [By Harvey Jones]

  LONDON --�I'm shopping for shares right now, should I pop�Aviva� (LSE: AV  ) (NYSE: AV  ) �into my basket?

  Problem play
  How do you solve a problem like Aviva? it has been looking like a bargain buy for several years, and I'm not the only Fool dazzled by its low, low price. But now it is beginning to look more than a little shop soiled. Is it really a bargain? And should I buy more now, while it still looks cheap?

• [By Royston Wild]

  Bubbly activity in developing geographies can create large opportunities for many London-listed firms. Today, I am looking at Aviva (LSE: AV  ) (NYSE: AV  ) and assessing whether its operations in these regions are likely to underpin solid earnings growth.

• [By Royston Wild]

  Today I am looking at�Aviva� (LSE: AV  ) (NYSE: AV  ) to see how it measures up.

  What are�Aviva's earnings expected to do?

Hot Financial Stocks To Watch Right Now: Pebblebrook Hotel Trust(PEB)

Pebblebrook Hotel Trust, through Pebblebrook Hotel, L.P., operates as a real estate investment trust. The company acquires and invests primarily in hotel properties located in the United States. It holds interests in the Doubletree Bethesda Hotel and Executive Meeting Center located in Bethesda, Maryland; Sir Francis Drake Hotel located in San Francisco, California; and InterContinental Buckhead Hotel located in Atlanta, Georgia. As a REIT, the company is not subject to federal income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. The company was founded in 2009 and is based in Bethesda, Maryland.

Advisors' Opinion:

• [By Rich Duprey]

  Hotel operator�Pebblebrook Hotel Trust (NYSE: PEB  ) announced today its second-quarter dividend of $0.16 per share, the same rate it paid last quarter after raising the payout 33% from $0.12 per share.

• [By Jonas Elmerraji]

  Small-cap hotel investment REIT Pebblebrook Hotel Trust (PEB) is setting up a similar pattern to the one in EXR -- with a few exceptions.

  PEB isn't forming an ascending triangle; support isn't in the same sort of uptrend in this stock. Instead, PEB is forming a rounding pattern with resistance at $28. Rounding patterns look just like they sound -- they indicate a shift in control from sellers to buyers. While this setup is most common as a "bottoming" pattern, PEB's price action doesn't change the implications if shares can break out above $28. That's our buy signal.

  Whenever you're looking at any technical price pattern, it's critical to think in terms of buyers and sellers. Triangles, rectangles and other price pattern names are a good quick way to explain what's going on in this stock, but they're not the reason it's tradable. Instead, it all comes down to supply and demand for shares.

  That resistance line at $28 is a price where there's an excess of supply of shares; in other words, it's a place where sellers have been more eager to take recent gains and sell their shares than buyers have been to buy. That's what makes the move above it so significant -- a breakout indicates that buyers are finally strong enough to absorb all of the excess supply above that price level. Wait for that signal to happen before you jump into this stock.

Hot Financial Stocks To Watch Right Now: Madison Covered Call & Equity Strategy Fund (MCN)

Madison/Claymore Covered Call & Equity Strategy Fund (the Fund), formerly Madison/Claymore Covered Call Fund, is a diversified, closed-end management investment company. The Fund�� primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Fund invests in a portfolio consisting primarily of large capitalization common stocks. The Fund will sell covered call options to seek to generate a reasonably steady production of option premiums.

Madison Asset Management, LLC is the Fund�� investment manager. Madison Asset Management, LLC is a wholly owned subsidiary of Madison Investment Advisors, Inc.

Advisors' Opinion:

• [By Robert Hsu]
  Name Type of Security� Recommendation� Kinder Morgan Energy Partners L.P. (NYSE: KMP) � MLP August 15, 2013� TeeKay LNG Partners L.P.� (NYSE: TGP) � MLP September 16, 2013� PowerShares S&P 500 BuyWrite Portfol ETF� (NYSE Arca: PBP)� Buy-Write ETF September 30, 2013� Madison Covered Call Equity Strtgy Fd (NYSE: MCN)� Buy-Write ETF September 30, 2013� Nuveen Equity Premium Opportunity Fund (NYSE: JSN)� Buy-Write ETF September 30, 2013� BlackRockEnhanced Dividend Achievers Tr (NYSE: BDJ)� Buy-Write ETF September 30, 2013� Vornado Realty Trust � (NYSE: VNO)� Real Estate
  Investment
  Trust September 26, 2013�
  
  

  Robert Hsu is the editor of Permanent Wealth Investor and a former hedge fund portfolio manager at Wall Street powerhouse Goldman Sachs. He retired from Goldman at age 31. He since has come out of retirement to establish and preside over his money management firm, Absolute Return Capital Advisors. His retirement experience has given him his current mission: helping investors like you achieve their goal of comfortable retirement through profitable income strategies.

• [By Robert Hsu]

  Here are four to consider:

  PowerShares S&P 500 BuyWrite ETF (PBP), yielding 4.09%
  
  Madison/Claymore Covered Call & Equity Strategy (MCN), yielding 8.94%
  
  Nuveen Equity Premium Opportunity Fund (JSN), yielding 9.19%
  
  BlackRock Enhanced Dividend Achievers (BDJ), yielding 7.39%
  
  

  The yield on these funds is very attractive. Even more attractive is the fact that many buy-write funds actually are selling at a discount to their net asset value.

Top 5 Biotech Stocks To Own Right Now

From the impact of Obamacare to cutting-edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week�to discuss the most fascinating developments in health care and their implications for long-term investors. In this week's edition, the team talks about The Atlantic's fifth annual Health Care Forum, biotechs in the news, two stocks investors need to watch, and more.

In the segment below, health-care analyst David Williamson highlights key takeaways from the panel of Farzad Mostashari, the National Coordinator for Health Information Technology for the United States. This part of the program focused on the future of health IT in the country and that while making big strides, the true impact of this technological revolution is still in the early innings.

Watch and find out and why it has captured the attention of venture capitalists and discover one stock investors may want to put on their radars.

What macro trend was Warren Buffett referring to when he said "This is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating at America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

Top 10 Safest Stocks To Own For 2015: Juno Therapeutics Inc (JUNO)

Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell.

To provide treatment, the Company harvests blood cells from a cancer patient, separate the appropriate T cells, activate the cells, insert the gene sequence for the CAR or TCR construct into the cells��Deoxyribonucleic Acid (DNA), and grow these modified T cells to the desired dose level. The modified T cells can then be infused into the patient or frozen and stored for later infusion. Once infused, the T cells are designed to multiply, through a process known as cell expansion, when they encounter the targeted proteins and to kill the targeted cancer cells.

CD19-Directed Product Candidates

The Company�� product candidates, such as JCAR015, JCAR017, and JCAR014, which use CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. The Company has rights to commercialize each of these product candidates across the world. The Company�� JCAR015 is an advanced development product candidate, and it has demonstrated clinically meaningful complete remission rates in adult patients with r/r ALL. JCAR015 uses the CD28 costimulatory domain and CD3 enriched peripheral blood mononuclear cells (PBMC), which requires fewer process steps for! manufacture than its defined cell composition product candidates. JCAR015 is being tested in a Phase I open label clinical trial of patients with r/r ALL for the treatment of refractory chronic lymphocytic leukemia.

JCAR017 also targets CD19, but differs from JCAR015 in several important respects. JCAR017 uses the 4-1BB costimulatory domain and a defined cell composition of CD4+ T cells and CD8+ T cells. JCAR017 is in development for pediatric patients with r/r ALL. JCAR017 is being evaluated in a Phase I/II clinical trial in pediatric r/r ALL.

JCAR014 also targets CD19. JCAR014 uses the 4-1BB costimulatory domain and is composed of CD8+ central memory T cells and CD4+ T cells in a defined ratio. JCAR014 is being evaluated in a Phase I/II trial as a treatment for a number of B cell malignancies in patients relapsed or refractory to standard therapies.

Additional Product Candidates

The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers not targeted by CD19-directed products, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung, and pancreatic cancers, as well as B cell malignancies that do not express CD19. The Company�� CD22 is a cell surface protein widely expressed on B lymphocytes. It is expressed by B cell malignancies, including non-Hodgkin�� lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The Company�� L1CAM, also known as CD171, is a cell-surface adhesion molecule that plays an important role in the development of a normal nervous system. It is overexpressed in neuroblastoma, and there is increasing evidence of aberrant expression in a variety of solid organ tumors, including glioblastoma and lung, pancreatic, and ovarian cancers.

The Company�� MUC-16 is a protein overexpressed in the ovarian cancers, but not on the surface of normal ovary cells. CA-125 is a protein found in the ! blood of ! ovarian cancer patients that results from the cleavage of MUC-16. CA-125 levels in the blood are a common test for ovarian cancer progression because they correlate with cancer progression. Its MUC-16/IL-12 product candidate uses its armored CAR technology. IL-12 is a cytokine that can help overcome the inhibitory effects that the tumor micro-environment can have on T cell activity.

The Company�� ROR-1 is a protein expressed in the formation of embryos, but in normal adult cells its surface expression is predominantly found at low levels on adipocytes, or fat cells, and briefly on precursors to B cells, or pre-B cells, during normal B cell maturation. ROR-1 is overexpressed on a variety of cancers including a subset of non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, and prostate cancer. It is expressed on B cell chronic lymphocytic leukemia and mantle cell lymphoma. The Company�� high-affinity TCR T cell product candidate targets WT-1, an intracellular protein that is overexpressed in a number of cancers, including adult myeloid leukemia, or AML, and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.

Advisors' Opinion:

• [By John Udovich]

  Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.

Top 5 Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors' Opinion:

• [By Ben Levisohn]

  Gilead’s not the only biotech benefiting from Roden’s largess. He expects a beat from Biogen Idec (BIIB) and raised his target to $130. He predicts good things from Amgen (AMGN), as well.

• [By Wallace Witkowski]

  Other earnings highlights in the coming week include Dow components McDonald�� Corp. (MCD) , DuPont (DD) , AT&T Inc. (T) , and Procter & Gamble Co. (PG) . Notable S&P 500 companies include Halliburton Co. (HAL) , Netflix Inc. (NFLX) �, Amgen Inc. (AMGN) �, TripAdvisor Inc. (TRIP) �, Amazon.com Inc. (AMZN) �, Colgate-Palmolive Co. (CL) �, Ford Motor Co. (F) �, Dow Chemical Co. (DOW) �, and United Parcel Service Inc. (UPS) �

• [By Maxx Chatsko]

  In the following video, Fool contributor Maxx Chatsko explains whether he thinks Gilead Sciences (NASDAQ: GILD  ) or Amgen (NASDAQ: AMGN  ) is the better buy. Both companies are trading at nearly identical market caps and have risen dramatically since the beginning of 2012 in anticipation of new blockbuster products. Both have robust pipelines stuffed full of potential at all levels of development. This is going to be a tough decision. If these companies are on your watchlist or if you're simply looking to add to a position, then you may want to use the current market volatility to your advantage.

Top 5 Biotech Stocks To Own Right Now: Bio-Path Holdings Inc (BPTH)

Bio-Path Holdings Inc is a development stage company. The Company, through its wholly owned subsidiary, Bio-Path, Inc. is engaged in the business of developing cancer therapeutics. As of December 31, 2011, the Company had licenses from The University of Texas M. D. Anderson Cancer Center (MD Anderson) for three lead products and nucleic acid delivery technology, including tumor targeting technology. The licenses provide drug delivery platform technology with composition of matter intellectual property for antisense that enables systemic delivery of antisense, formulation intellectual property for systemic delivery of small interfering Ribonucleic acid (RNA) (siRNA) and small molecules for treatment of cancer. The Company issued a press release announcing that the United States Food and Drug Administration (FDA) had allowed an IND (investigational new drug) for its lead cancer drug candidate liposomal BP-100-1.01 (or Liposomal Grb-2 or L-Grb-2) to proceed into clinical trials.

In February, 2012, the Company completed requirements for treating patients in the second cohort. The dose being used for treatment in the third cohort is double the dose that was used to treat patients in the second cohort. At the end of February, 2012, enrollment continued in the third cohort of the clinical trial and patients are being treated.

BP-100-1.01

BP-100-1.01 is the Company's lead lipid delivery antisense drug candidate, which is being clinically tested in patients having acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL). Receipt of an IND allowed the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients. Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center. As of December 31, 2011, the trial is in the middle of ! testing the third dose in patients.

BP-100-2.01

BP-100-1.02 is Liposomal Bcl-2 (also L-Bcl-2), another liposomal antisense drug candidate that was licensed from MD Anderson. This drug has pre-clinical testing data package. The target protein for this drug candidate, Bcl-2, is involved in regulating programmed cell death. In cancer, the Bcl-2 protein can over-express, which can lead to a situation, in which the Bcl-2 protein blocks the cell�� normal death signals, making the cancer cell resistant to chemotherapy. Types of cancer potentially treatable with L-Bcl-2 include lymphoma, prostate cancer, small cell lung cancer, breast cancer, melanoma, chronic lymphoid leukemia (CLL) and several others.

Advisors' Opinion:

• [By Lisa Levin]

  Bio-Path Holdings (NASDAQ: BPTH) shares declined 5.66% to touch a new 52-week low of $2.50. Bio-Path shares have jumped 349.15% over the past 52 weeks, while the S&P 500 index has gained 19.24% in the same period.

Top 5 Biotech Stocks To Own Right Now: Neurocrine Biosciences Inc.(NBIX)

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development include Elagolix, a Phase II drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; GnRH Antagonists for men?s and women?s health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott International Luxembourg S.�r.l. to develop and commercialize elagolix and GnRH antagonists for women?s and men?s health indications; and Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Roberto Pedone]

  Another stock that's starting to trend within range of triggering a major breakout trade is Neurocrine Biosciences (NBIX), which discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. This stock has been a hot name with bulls so far in 2013, with shares up 57%.

  If you look at the chart for Neurocrine Biosciences, you'll notice that this stock recently gapped down sharply from $16.74 to below $11.50 a share with heavy downside volume flows. Following that gap down, shares of NBIX went on to continue its trend lower and the stock hit a new low of $10.42 a share. Shares of NBIX have started to rebound off that $10.42 low and it's now moving within range of triggering a major breakout trade.

  Traders should now look for long-biased trades in NBIX if it manages to break out above some near-term overhead resistance levels at its 200-day moving average of $11.92 a share and above its gap down day high of $12.17 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 894,145 shares. If that breakout triggers soon, then NBIX will set up to re-fill some of its previous gap down zone from September that started at $16.74 a share. Some possible upside targets for NBIX if it gets into that gap with volume are $14 to $15 a share.

  Traders can look to buy NBIX off any weakness to anticipate that breakout and simply use a stop that sits right below support at $11 a share, or below that recent low of $10.42 a share. One can also buy NBIX off strength once it takes out that breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Shares of Neurocrine Biosciences (NASDAQ: NBIX) got a boost, shooting up 57.43 percent to $15.37 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.

• [By Ben Levisohn]

  Yes, say the folks at Nomura, who recommend buying�Celgene (CELG), Receptos
  (RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why:

Europe's Stocks to Watch: Alstom, ING, EasyJet

Alstom is in focus Wednesday after the French engineering firm announced plans to raise between €1 billion ($1.35 billion) and €2 billion from the sale of assets, including a stake in the unit that makes the high-speed TGV and Eurostar trains.

It also said it will speed up a cost-cutting plan after booking fewer orders in the first half of the year than in the same period a year ago.

During the third quarter, Alstom booked orders worth €9.43 billion, down from €12.13 billion in the same period a year ago as demand in emerging markets weakened for Alstom’s turbines and other equipment for power plants, the company said.

The company said net profit fell 2.8% in the first half to €375 million from €386 million in the same period a year ago. Sales fell to €9.73 billion from €9.75 billion.

Still, the announcement of a new cost saving program and an asset sale plan “should ease some market concerns around the company, following a somewhat weak free cash flow performance” in the first half, said Citigroup.

And investors seem to agree. The company’s shares have climbed over 5% in early trade Wednesday.

Hot Medical Companies To Buy For 2015

In a week of European banking news, Dutch bank ING announced Wednesday it had agreed with European Union competition authorities to speed up its restructuring plan after experiencing problems finding a buyer for its Japanese business.

The unit will now be integrated into ING’s European insurance business, which is being readied for an initial public offering in 2014. As a result, the restructuring now will be completed by the end of 2016, two years earlier than previously planned, ING said.

ING was ordered by the EU to sell its global insurance arm to get approval for a government bailout received in 2008.

At the same time the Dutch lender posted a sharp drop in net profit for the third quarter to  €101 million ($136 million), compared with €659 million a year earlier, as the bottom line was hit by a €950 million loss on the sale of the bank’s South Korean insurance business.

However, underlying profit, which excludes the impact from divestments and other special items, rose 8.3% to €1.22 billion, ING said.

Shares in the bank have climbed over 4% Wednesday. The plan to put the Japanese insurance business into the European IPO is a smart move, according to Rabobank analyst Cor Kluis. The unit might have fetched only €400 million in a forced sale but will warrant a higher valuation through the IPO , he added.

Shares in easyJet climb over 2% Wednesday after the budget airline reported a solid 5.4% rise in the number of passengers carried in October compared with the same month last year.

In addition, the load factor, the number of passengers as a proportion of the number of seats available for passengers, came in at 89.1%, a rise of 0.7 percentage points compared with October 2012.

These numbers will likely come as a relief to investors, as rival Ryanair on Monday cut its full-year net profit guidance, blaming continued lower average fares.

On Oct. 3, easyJet raised its pretax profit guidance for fiscal 2013 to between £470 million ($753.56 million) and £480 million, from previous expectations of £450 million to £480 million.

However, the news wasn’t universally good for easyJet Wednesday. U.K.-based banking giant HSBC downgraded its investment recommendation for the airline to underweight from neutral, citing near term deteriorating revenue momentum.

“Long term, we think competitor moves to adopt similar product and marketing to easyJet are unlikely to match the U.K. business's execution, but will reduce differentiation between the companies in the eyes of consumers,” said HSBC, in a note to clients.

The bank also pointed out that easyJet’s shares are up more than 90% over the past 12 months, so some consolidation may be in order in the near future.

Top 10 High Dividend Stocks To Invest In 2015

Top 10 High Dividend Stocks To Invest In 2015: Merge Healthcare Incorporated.(MRGE)

Merge Healthcare Incorporated provides health information technology interoperability solutions. It provides products ranging from standards-based development toolkits to clinical applications. The company offers Merge iConnect, an interoperable image exchange and management suite; cardiovascular information systems to bring automation to the cardiac cath lab; radiology solutions to integrate images and information; lab information systems; orthopaedic software to automate workflow and digital templating; clinical trials tools to transform data into intelligence; and perioperative solutions to streamline the pre-surgical experience. It also offers advanced image viewers, developer toolkits, and related hardware products. The company?s products are used by healthcare providers, vendors, and researchers. Merge Healthcare Incorporated was founded in 1987 and is based in Chicago, Illinois.

Advisors' Opinion:

• [By Sally Jones]

  Here’s a look at three application software companies currently on a 52-week low and still held by a few billionaires. The9 Ltd. (NCTY), Merge Healthcare Inc. (MRGE) and FAB Universal Corp. (FU) are more than 52% off a 52-week high.

• [By Roberto Pedone]

  Another stock that's starting to move within range of triggering a breakout trade is Merge Healthcare (MRGE), which develops software solutions that facilitate the sharing of images to create a more effective and efficient electronic health care experience for patients and physicians. This stock hasn't done much in 2013, with shares up just over 8% so far.

  If you take a look at the chart for Merge Healthcare, you'll notice that this stock has been trending sideways since it gapped down in August, with shares moving between $2.35 on the downside and $2.98 on the upside. Shares o! f MRGE are now starting to trend back above its 50-day moving average of $2.65 a share. That move is quickly pushing the stock within range of triggering a big breakout trade above the upper end of its sideways trading chart pattern.

  Market players should now look for long-biased trades in MRGE if it manages to break out above some near-term overhead resistance levels at $2.82 to $2.98 a share, and then once it takes out its 200-day moving average at $3.08 and its gap down day high of $3.20 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action o 793,997 shares. If we get that move soon, then MRGE will set up to re-fill some of its previous gap down zone from August that started at $4.60 a share.

  Traders can look to buy MRGE off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $2.55 to $2.54 a share, or below that recent low of $2.35 a share. One can also buy MRGE off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-high-dividend-stocks-to-invest-in-2015.html

Top US Stocks To Watch For 2014

The FCC pauses its review of the Comcast-Time Warner Cable deal sending the merger potentially in 2015. NEW YORK (CNNMoney) Those waiting for a Comcast-Time Warner Cable merger -- and possibly improved cable service in cities like New York City and Los Angeles -- are going to have to hold out a bit longer.

Government regulators at the Federal Communications Commission have paused the unofficial 180-day clock on the review of the proposed deal between the two cable giants.

The delay was reported on Wednesday, one day before Comcast reported better-than-expected third quarter earnings.

"The stoppage... doesn't reflect any substantive concerns with our transaction," Comcast CEO Brian Roberts told investors on a conference call on Thursday. "We continue to believe that the review will get completed, as we previously said, and hopefully close sometime early in 2015."

Best Bank Stocks To Watch Right Now: Powershares Dynamic Food & Beverage Portfolio (PBJ)

PowerShares Dynamic Food & Beverage Portfolio (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Dynamic Food & Beverage Intellidex Index (the Food & Beverage Intellidex). The Food & Beverage Intellidex consists of stocks of 30 United States food and beverage companies. These are companies that are principally engaged in the manufacture, sale or distribution of food and beverage products, agricultural products and products related to the development of new food technologies. These companies may include companies that sell products and services, such as meat and poultry processing, and wholesale and retail distribution and warehousing of food and food-related products, including restaurants, grocery stores, brewers, distillers and vintners, as well as companies that manufacture and distribute products, including soft drinks, packaged food products (such as cereals, pet foods and frozen foods), health food and dietary products. Stocks are selected principally on the basis of their capital appreciation potential as identified by the AMEX (the Intellidex Provider) pursuant to its Intellidex methodology. The Fund�� investment advisor is PowerShares Capital Management LLC.

The Food & Beverage Intellidex is adjusted quarterly, and the Fund, using an indexing investment approach, attempts to replicate the performance of the Food & Beverage Intellidex. The Fund generally will invest in all of the stocks comprising the Food & Beverage Intellidex in proportion to their weightings in the Food & Beverage Intellidex. The Fund will normally invest at least 80% of its total assets in common stocks of food and beverage companies. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Food & Beverage Intellidex.

Advisors' Opinion:

• [By John Udovich]

  Small cap ingredients stock Balchem Corporation (NASDAQ: BCPC) jumped 22.76% yesterday on news about an acquisition, meaning its worth taking a closer look at the stock along with potential peers like small cap MGP Ingredients Inc (NASDAQ: MGPI) and the PowerShares Dynamic Food & Beverage ETF (NYSEARCA: PBJ).

Top US Stocks To Watch For 2014: Sprott Physical Gold Trust (PHYS)

Sprott Physical Gold Trust (the Trust) is a closed-end mutual fund trust. The Trust was created to invest and hold substantially all of its assets in physical gold bullion. The Trust seeks to provide an exchange-traded investment alternative for investors interested in holding physical gold bullion. The Trust invests primarily in long-term holdings of unencumbered, fully allocated, physical gold bullion and does not speculate with regard to short-term changes in gold prices. Sprott Asset Management LP (the Manager) is the manager and RBC Dexia Investor Services Trust (RBC Dexia), a trust company, is the trustee of the Trust.

The Trust employs two custodians. The Royal Canadian Mint (Mint) acts as custodian for the Trust's physical gold bullion, pursuant to a precious metals storage agreement between the Manager, for and on behalf of the Trust, and the Mint, to which it refers as the precious metals storage agreement. RBC Dexia acts as custodian of the Trust's assets other than physical gold bullion pursuant to the trust agreement. As of December 31, 2010, the Trust held 90% of its total net assets in physical gold bullion in London Good Delivery bar form. The Trust does not invest in gold certificates or other financial instruments that represent gold or that may be exchanged for gold.

In making investments on behalf of the Trust, the Manager is subject to certain investment and operating restrictions, to which the Trust refers to as the Investment and Operating Restrictions. The Investment and Operating Restrictions provide that the Trust will invest in and hold a minimum of 90% of the total net assets of the Trust in physical gold bullion in London Good Delivery bar form and hold no more than 10% of the total net assets of the Trust, at the discretion of the Manager, in physical gold bullion (in London Good Delivery bar form or otherwise), gold coins, debt obligations of or guaranteed by the Government of Canada or a province of Canada or by the Government of the United St! ates or a state thereof.

The Trust will invest in short-term commercial paper obligations of a corporation or other person whose short-term commercial paper is rated R-1 (or its equivalent, or higher) by Dominion Bond Rating Service Limited or its successors, or assigns or F1 (or its equivalent, or higher) by Fitch Ratings or its successors, or assigns or A-1 (or its equivalent, or higher) by Standard & Poor's or its successors, or assigns or P-1 (or its equivalent, or higher) by Moody's Investor Service or its successors, or assigns, interest-bearing accounts and short-term certificates of deposit issued or guaranteed by a Canadian chartered bank or trust company, money market mutual funds, short-term government debt or short-term investment grade corporate debt, or other short-term debt obligations approved by the Manager from time to time. The Trust will not purchase, sell or hold derivatives.

Advisors' Opinion:

• [By Cameron Swinehart]

  Going forward I will be looking to add investments on my watchlist and trim other positions. It will be interesting to see how an overweight commodity portfolio will perform relative to the rest of the market.

   Cost Basis# SharesCurrent Price% of PortfolioCurrent ValueReturnMetal/Miners      Sprott Physical Gold Trust (PHYS)$12.4985$11.043.75%$938.40-13.13%Sprott Physical Silver Trust (PSLV)$7.95125$8.744.37%$1,092.509.04%FreePort-McMoran (FCX)$31.6731$33.874.20%$1,049.976.50%Ishares MSCI Global Gold Miners ETF (RING)$13.0695$10.644.04%$1,010.80-22.74%Energy      Statoil ASA(STO)$21.7940$22.683.63%$907.203.92%Vanguard Natural Resources LLC (VNR)$27.5636$27.874.01%$1,003.321.11%ConocoPhillips (COP)$63.6822.43$71.006.37%$1,592.5310.31%Agriculture      CVR Partner LP (UAN)$26.3630.9$18.932.34%$584.94-39.25%Adecoagro$6.78125$7.443.72%$930.008.87%Archer-Daniels Midland (ADM)$34.8030$37.244.47%$1,117.206.55%Mixed Commodity      Powershares DB Commodity Index (DBC)$26.3540$25.954.15%$1,038.00-1.54%Sprott Resource Corp$3.34400$2.714.34%$1,084.00-23.25%    Total % of portfolio49.40%               Cost Basis12,666.00      Current Value12,348.86      Return-2.50%  Source: Investing For The Future Surge In Commodity Prices

  Disclosure: I am long ADM, FCX, UAN, AGRO, RING, VNR, SCPZF.PK, COP, DBC, PHYS, PSLV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)

• [By Daniel Gibbs]

  Gold trusts and ETFs
  One of the easiest ways to profit off of a rising gold price is to buy shares in one of the various exchange-traded gold trusts. These are essentially closed-end funds that own physical gold bullion located in a vault. Each share of the trust represents a fractional ownership share of the physical bullion in the vault. Thus, these trusts could be an easy way to purchase gold exposure directly on an exchange. One example of a trust like this is the�Sprott Physical Gold Trust (NYSEMKT: PHYS  ) .

• [By Daniel Cook]

  If you are partial to Canadians, or just a little nervous about securing your gold, Sprott Physical Gold Trust (NYSEMKT: PHYS  ) is another viable option. Gold is stored at the Royal Canadian Mint, and I think monthly dusting and shining of the bars is included in Sprott's 0.42% management fee.

Top US Stocks To Watch For 2014: John Wiley & Sons Inc (JWA)

John Wiley & Sons, Inc., incorporated on January 15, 1904, is a global provider of knowledge and knowledge-based services in areas of research, professional development and education. Core businesses produce scientific, technical, medical and scholarly research journals, reference works, books, database services, and advertising; professional books and certification, assessment and training services, and education content and services, including online program management for colleges and universities and integrated online teaching and learning resources for instructors and students. The Company sells its products to customers in the Middle East (including Iran and Syria), Africa (including Sudan), Cuba, and other developing markets where it does not have operating subsidiaries. In April 2014, the Company acquired Profiles International, a provider of employment assessment and talent management solutions.

Research

The Company�� Research business serves the world�� research and scholarly communities and is a publisher for professional and scholarly societies. Research�� mission is to support researchers, professionals and learners in the discovery and use of research knowledge to achieve results that help shape the future. Research products include scientific, technical, medical and scholarly research journals, books, major reference works, databases, clinical decision support tools and laboratory manuals and workflow tools, in the publishing areas of the physical sciences and engineering, health sciences, social science and humanities and life sciences. Research customers include academic, corporate, government, and public libraries; researchers; scientists; clinicians; engineers and technologists; scholarly and professional societies, and students and professors. The Company�� Research products are sold and distributed globally, online and in print through multiple channels, including research libraries and library consortia, independent subscription agents, direct sa! les to professional society members, bookstores, online booksellers and other customers. Publishing centers include Australia, Germany, India, Singapore, the United Kingdom and the United States. Research accounted for approximately 57% of total Company revenue (fiscal 2013). The Company�� Research business is a provider of content and services in evidence-based medicine (EBM). Through the Company�� alliance with The Cochrane Collaboration, the Company publishes The Cochrane Library.

Wiley Online Library, the online publishing platform for the Company�� Research business, is a multidisciplinary collections of online resources covering life, health and physical sciences, social science and the humanities. Wiley Online Library delivers seamless integrated access to over four million articles from 1,500 journals, 13,000 online books, and hundreds of reference works, laboratory protocols and databases. Wiley Online Library provides the user with intuitive navigation, enhanced discoverability, expanded functionality and a range of personalization options. Wiley Open Access is the Company�� publishing program for open-access research articles. Under the Wiley Open Access business model, research articles submitted by authors are published and compiled by subject area into open-access journals. In addition to Wiley Open Access, the Company provides authors with the opportunity to make their individual research articles that were published within the Company�� paid subscription journals freely available to the general public through OnlineOpen.

Professional Development (PD)

The Company�� Professional Development business acquires, develops and publishes professional books, subscription products, certification and training services and online applications in the areas of business, finance, accounting, workplace learning, management, leadership, technology, behavioral health, engineering/ architecture and education. Products are developed in print and digitally ! for world! wide distribution through multiple channels, including major chains and online booksellers, independent bookstores, libraries, colleges and universities, warehouse clubs, corporations, direct to consumer, websites and other online applications. Publishing centers include Australia, Canada, Germany, India, Singapore, the United Kingdom and the United States. Professional Development accounted for approximately 24% of total Company revenue in fiscal year 2013. Professional Development revenue by product type includes eBooks and Print Books; Online Training and Assessment which is revenue from the sale of products and services focusing on workplace effectiveness and career success; Publishing Rights which is revenue from the licensing of the right to republish Wiley content either online or in print; Journal Subscriptions online and in print to professionals, and Other.

Education

The Company�� Education business produces educational content and services, including online program management for colleges and universities and integrated online teaching and learning resources for instructors and students. Education�� mission is to help teachers teach and students learn by delivering to students, faculty and institutions throughout the world personalized content, tools and services that demonstrate results. Education offers products and services principally delivered through college bookstores and online distributors, with customers having access to content in multi-media formats, as well as the traditional textbook. Education�� solutions are available in each of its publishing disciplines, including the sciences, engineering, computer science, mathematics, business and accounting, statistics, geography, hospitality and the culinary arts, education, psychology and modern languages. Education accounted for approximately 19% of total Company revenue in fiscal year 2013. Education revenue by product type includes eBooks and Print Textbooks; Online Program Management; WileyPLUS, the ! Company�! � online learning solution; revenue from the licensing of publishing content rights and Other Nontraditional and Digital Products, such as custom publishing and other content adaption��.

Education offers online learning solutions including WileyPLUS, it�� research-based, online environment for effective course teaching and learning that is integrated with a complete digital textbook. WileyPLUS improves student learning through instant feedback, personalized learning plans, and self- evaluation tools and a range of course-oriented activities, including online planning, presentations, study, homework and testing. The Company also provides the services of the Wiley Faculty Network, a global community of faculty that offers guidance, training, and resources. Through the Wiley Faculty Network, instructors and administrators can collaborate with each other, attend virtual and live events, and utilize a wealth of resources all designed to help them grow as educators.

Journal Products

The Company publishes approximately 1,600 Research and Professional Development journals. Journal subscription revenue and other related publishing income, such as advertising, backfile sales, the licensing of publishing rights, journal reprints and individual article sales accounted for approximately 48% of the Company�� consolidated fiscal year 2013 revenue. The journal portfolio includes titles owned by the Company, in which case they may or may not be sponsored by a professional society; titles owned jointly with a professional society; and titles owned by professional societies and published by the Company pursuant to long-term contracts. The Company also enters into agreements with outside independent editors of journals that state the duties of the editors, and the fees and expenses for their services. The Company sells journal subscriptions directly through Company sales representatives; indirectly through independent subscription agents; through promotional campaigns, and thro! ugh membe! rships in professional societies for those journals that are sponsored by societies. Journal subscriptions are primarily licensed through contracts for online content delivered through the Company�� online platform, Wiley Online Library.

Book Products

The Company�� Book products and book related publishing revenue, such as advertising and the sale of publishing rights, accounted for approximately 48% of the Company�� fiscal year 2013 revenue. The Company enters into agreements with authors that state the terms and conditions under which the materials will be published, the name in which the copyright will be registered, the basis for any royalties, and other matters. The Company develops content in a digital format that can be used for online and print products, resulting in productivity and efficiency savings, and enabling print-on-demand delivery. Book content is available online through Wiley Online Library, WileyPLUS, Custom Select and other platforms. Ebooks are delivered to intermediaries, including Amazon, Apple and Google for re-sale to individuals in various industry-standard formats, which are now also the preferred deliverable for licensees of all types, including foreign language publishers.

Other Digital Products and Services

The Company is focused on delivering content-enabled services which improve learning, career management and effectiveness for its target communities. The Inscape and ELS businesses, along with the Company�� Pfeiffer brand, represent the Company�� professional training and assessment services. These businesses offer a variety of classroom learning solutions and e-learning activities that are delivered to customers directly through online digital delivery platforms and also through an authorized distributor network of independent consultants, trainers and coaches. The Company�� professional training and assessment services offer highly flexible packages and modules for its customers that include online pre-w! ork and p! rofile assessments, self-study materials, online videos, mobile apps and other sophisticated planning tools.

The Company generates advertising revenue from print and online journal subscription products; its online publishing platform, Wiley Online Library; the Wiley Job Network, a full service online job board; online events such as webinars and virtual conferences; community interest websites such as spectroscopyNOW.com and websites for the Company�� brands like Dummies.com. The Company�� publications and services are sold throughout most of the world through operations located in Europe, Canada, Australia, Asia, and the United States.

Advisors' Opinion:

• [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]

  John Wiley & Sons Inc.(JWA) on Tuesday said it agreed to buy privately held French management solutions company CrossKnowledge for $175 million in cash. CrossKnowledge’s customizable offerings–including skills assessment, training and certifications–are delivered through a cloud-based platform.

Top US Stocks To Watch For 2014: Saes Getters SpA (SG&A)

SAES Getters SpA is an Italy-based company primarily engaged in the production of getters and metal dispensers. The Company structures its business into three main units: Industrial Applications, which includes getters and metal dispensers used in light sources and electron vacuum devices, getters for microelectronic and micromechanical systems, pumps for vacuum systems, getters for solar collectors, products for thermal insulation, and gas purifier systems; Shape Memory Alloys, which includes shape memory alloy semi-finished products, components and devices for medical and industrial applications, and Information Displays, which includes getters and metal dispensers for liquid crystal displays, and barium getters for cathode ray tubes. Additionally, through the Business Development Unit, the Company produces dryers and getters for organic light-emitting diode (OLED), sealants for solar panels and energy storage getter devices. Advisors' Opinion:

• [By Jason Rivera]

  To help facilitate this destruction of value has been that Koss has bought back a lot of its shares as the company has been overvalued. The below quote is from its most recent annual report.
  In April of 1995, the Board of Directors approved a stock repurchase program authorizing the Company to purchase from time to time up to $2,000,000 of its common stock for its own account. Subsequently, the Board of Directors periodically has approved increases in the stock repurchase program. As of June 30, 2012, the most recently approved increase was for additional purchases of $2,000,000, which occurred in October of 2006, for an aggregate maximum of $45,500,000, of which $43,360,247 had been expended through June 30, 2012 . No purchases were made during the year ended June 30, 2012. The Company intends to effect all stock purchases either on the open market or through privately negotiated transactions and intends to finance all stock purchases through its own cash flow or by borrowing for such purchases.As you can see from this page, most of KOSS' margins have dropped substantially since 2007. Especially of note is its operating margin, ROE and ROIC. Book value per share, cash flow per share, revenue and working capital have all dropped substantially as well. Normally when I have evaluated companies' cost of goods sold rising is what has caused the above metrics to drop, but that has stayed relatively stable over the years at KOSS. The culprit in this case is selling, general and administrative (SG&A) related expenses expressed below as a percentage of its sales. The following numbers were taken from Morningstar:

• [By GURUFOCUS]

  For investors, Qualcomm understand the benefits of cloud services. It seems there are numerous questions unresolved. Over the last decade, pharmaceutical companies have been aggregating years of research and development data into medical databases, initiating overhauls of its R&D and selling, general and administrative (SG&A) segments for Pharma. A company willing to build their capabilities, and open to a new view of value will likely achieve better outcomes. Delivering support, personalization, scalability, speed and flexibility are attractive areas for growth.

Top US Stocks To Watch For 2014: Gold Fields Ltd (GFI)

Gold Fields Limited (Gold Fields) is a holding company. Gold Fields is engaged in gold mining and related activities, including exploration, extraction, processing and smelting. Gold Fields is a producer of gold and holder of gold reserves in South Africa, Ghana, Australia and Peru. In Peru, Gold Fields also produces copper. Gold Fields is primarily involved in underground and surface gold and copper mining and related activities. Gold Fields also has an interest in a platinum group metal exploration project in Finland. Gold bullion is its principal product, which is produced in South Africa, Ghana and Australia and sold in South Africa and internationally. In addition, Gold Fields has gold and other precious metal exploration activities and interests in Africa, Eurasia, Australasia and the Americas. The Company holds 34.9% interest in Rand Refinery Limited.

On June 22, 2011, Gold Fields acquired the 18.9% interest of IAMGold Corporation (IAMGold), which increased Gold Fields��interest in each of the Tarkwa and Damang gold mines from 71.1% to 90.0%. On April 15, 2011, it acquired further interest in Gold Fields La Cima S.A.A. (La Cima). During the year ended December 31, 2011, the Company acquired a 21.8% interest in Timpetra Resources Limited.

KDC Operation

The KDC mine is located in the Gauteng Province of South Africa in the Far West Rand mining district, some 60 kilometers southwest of Johannesburg. KDC is consists of the Driefontein and Kloof mines. In 2011, KDC produced 1.1 million ounces of gold. KDC is consists of 13 producing shaft systems that mine different contributions from pillars and open ground, five gold plants of which two process mainly underground ore and three process mainly surface material. The KDC operation is engaged in both underground and rock dump mining. In total, during 2011, there were 13 fatalities at KDC. Of these, five were due to seismic related falls of ground, five resulted from gravity related falls of ground, two related! to tramming operations and one related to a person falling from height.

Beatrix Operation

The Beatrix operation is located in the Free State Province of South Africa, some 240 kilometers southwest of Johannesburg, near Welkom and Virginia, and consists of the Beatrix mine. Beatrix operates under mining rights covering a total area of approximately 16,800 hectares. Beatrix is an underground only operation. Beatrix has four shaft systems, with five ventilation shafts to provide additional up-cast and down-cast ventilation capacity and is serviced by two metallurgical plants. It is a shallow to intermediate-depth mining operation, at depths between 700 meters and 2,200 meters below surface. In 2011, Beatrix produced 0.347 million ounces of gold. Beatrix is managed as three operational sections: the North Section, the South Section and the West Section. The Beatrix mine is engaged in underground and surface mining. It had five fatalities at Beatrix, in 2011.

South Deep Operation

South Deep is situated adjacent to KDC, in the Gauteng Province of South Africa. South Deep is a capital project and remains a developing mine. South Deep is engaged in underground mining and is consists of one metallurgical plant and two operating shaft systems, the older South Shaft complex and the newer Twin Shaft complex. The South Shaft complex includes a main shaft and three sub-vertical (SV) shafts, two of which are operational. The Twin Shaft complex consists of a single-barrel shaft and an adjacent bratticed ventilation shaft, or the Twins Main Ventilation Shaft. While the Twin Shaft complex forms the center of production and capital development activities, opening up, equipping and diamond drilling operations are being conducted in the South Shaft area in order to access new mining areas.

The South Shaft complex operates to a depth of 2,650 meters below surface and the Twin Shaft complex operates to a depth of 2,995 meters below surface. In 2011, South Deep! produced! 0.273 million ounces of gold. During 2011, the South Deep plant treated an average of 0.2 million tons per month (excluding Kloof mine toll treatment) consisted of an average of 167,000 tons per month of underground material and 31,000 tons per month of surface material from South Deep.

Ghana Operations

Gold Fields Ghana Limited (Gold Fields Ghana), which holds the interest in the Tarkwa mine. The Tarkwa mine is located in southwestern Ghana, about 300 kilometers by road west of Accra. The Tarkwa mine consists of several open pit operations on the original Tarkwa property and the adjacent southern portion of the property, together with a heap leach facility, referred to as the North Plant Heap Leach Facility. The capacity of the facility is 3.3 million tons per annum. The total treatment capacity including the North Plant, the High Pressure Grinding Roll Facility and the carbon in leach (CIL) Plant is estimated to be 24 million tons per annum. The Tarkwa mine operates under mining leases with a total area of approximately 20,800 hectares, the entirety of which are surface operations. In 2011, Tarkwa produced 0.717 million ounces of gold, of which 0.576 million ounces were attributable to Gold Fields.

Abosso Goldfields Limited (Abosso), which owns the interest in the Damang mine. The Damang deposits are located in the Wassa West District in southwestern Ghana approximately 330 kilometers by road west of Accra and approximately 30 kilometers by road northeast of the Tarkwa mine. The Damang mine consists of an open pit operation with a semi-autogenous grinding (SAG) mill and CIL processing plant. Damang operates under a mining lease with a total area of approximately 8,100 hectares. In 2011, the Damang mine produced 0.218 million ounces of gold, of which 0.175 million ounces.

Australia Operations

Gold Fields owns the St. Ives and Agnew gold mining operations in Australia. St. Ives is located 80 kilometers south of Kalgoorlie and 20 kilometer! s south o! f Kambalda, straddling Lake Lefroy in Western Australia. It holds exploration licenses, prospecting licenses and mining leases covering a total area of approximately 97,700 hectares. St. Ives is both a surface and underground operation, with a number of open pits, four operating underground mines, a metallurgical carbon in pulp (CIP) plant and a heap leach facility. In 2011, St. Ives produced 0.465 million ounces of gold. St. Ives sources production from a variety of underground and surface operations. Exploration activities are continuing with a view to extending the life of the mine.

Production at the Argo underground mine continued throughout, during 2011. Greater Revenge Complex operation utilizes open pit and lake sediment mining methods. Cutbacks of the Agamemnon and Mars Minotaur Link pits were mined, during 2011. The Belleisle deposit lies in the Greater Revenge Area adjacent to the depleted Mars open pit. The final 20,000 ounces were mined from Belleisle, in 2011 and the mine was closed, in May 2011. Cave Rocks is located approximately six kilometers to the west of the Kambalda West township. The Leviathan open pit is based on the expansion of a pre-existing open pit located approximately two kilometers southeast of the Lefroy processing plant. The mine utilizes conventional truck and shovel mining practices.

Construction at the Athena mine reached commercial levels of production, in July 2011. The first ore extraction from Hamlet occurred, in November 2011. As of December 31, 2011, Athena ahd a life of mine of four years and Hamlet had a life of seven years with prospects of extensions to those lives. Underground mining activities at Belleisle, Cave Rocks and Argo were undertaken under an agreement with Carlowen Proprietary Ltd, which trades as GBF Underground Mining (GBF). Leighton Contractors Proprietary Limited (Leighton) performs the surface mining at St. Ives under an alliance agreement. Leighton provides employees and equipment for mining ore and waste from the! open pit! mines. Agnew is located 23 kilometers west of Leinster, approximately 375 kilometers north of Kalgoorlie and 630 kilometers northwest of Perth, Western Australia.

The Company holds exploration licenses, prospecting licenses and mining leases covering a total area of approximately 54,000 hectares. Agnew operated both an underground and the Songvang open pit, in 2011. Underground mining is conducted from the Waroonga Underground Complex which consists of multiple ore zones. Agnew has one metallurgical plant. Agnew is serviced by sealed road infrastructure to the mine gate. In 2011, the operation produced 0.194 million ounces of gold. The principal production source, in 2011, at Agnew was the Waroonga underground mining complex. The northern cutback of the Songvang open pit commenced, in 2011. The Waroonga Underground Complex includes underground mining of the Kim South, Rajah and Main Lode ore bodies. The mining method involves longhole open stoping with paste filling. Waroonga underground performance averaged 52,000 tons per month, in 2011.

Peru Operation

Gold Fields owns 98.5% economic interest in the Cerro Corona mine through its shareholding in La Cima. Cerro Corona mine forms part of a porphyry copper-gold deposit situated within the Hualgayoc Mining District in northern Peru. It is located in the part of the Western Cordillera of the Andes, in northern Peru, close to the headwaters of the Atlantic continental basin. Cerro Corona is located approximately 80 kilometers by road north of the City of Cajamarca. Cerro Corona holds mining leases covering a total area of approximately 1,600 hectares and the project was developed over an area of 940 hectares. In 2011, the operation produced 0.161 million ounces of gold and 38,641 tons of copper for a total of 0.383 million gold equivalent ounces, of which 0.159 million ounces of gold and 38,061 tons of copper for a total of 0.377 million gold equivalent ounces were attributable to Gold Fields.

Advisors' Opinion:

• [By Ben Levisohn]

  As a result, Chidley and team upgraded Agnico Eagle Mines (AEM) and�Yamana Gold (AUY) to Neutral from Underweight, and raised Barrick Gold (ABX), Goldcorp (GG) and Iamgold (IAG) to Overweight from Neutral.�Gold Fields (GFI) was downgraded “due to increased risk and also reduced expectations for the South Deep operation,” Chidley says.

• [By Ben Kramer-Miller]

  Furthermore, several events have transpired that have made me more confident in my position that Barrick Gold should be avoided by investors in gold mining companies and perhaps shorted as a hedge against a long gold portfolio.

  The company's development of its Pascua Lama project in Chile is delayed after the court of appeals ruled that "the company must complete Pascua-Lama's water management system in compliance with the project's environmental permit to the satisfaction of Chile's Superintendence of the Environment (Superintendencia del Medio Ambiente or "SMA") before resuming construction activities in Chile."The company sold its Barrick Energy Inc. subsidiary for roughly $455 million Canadian. It took a write-down of $500 million in the second quarter because it carried Barrick Energy on its books for nearly $1 billion.The company sold its Yilgarn South Assets to Gold Fields (GFI) for $300 million.The company slashed its dividend to $0.05 per share per quarter from $0.20 per share per quarter.

  As I hope to demonstrate the first three events are very telling of the company's inability to manage shareholders' capital (the fourth is a natural consequence of this). Ultimately one can question the alignment between shareholders' interests and management, and that a long position in Barrick Gold shares cannot be justified.

Top US Stocks To Watch For 2014: Greengro Technologies Inc (GRNH)

GreenGro Technologies Inc., formerly Authoriszor Inc., provides management services for the planning, construction, staffing and operation of medical marijuana dispensaries, and nurseries on behalf of non-profit patient co-operatives. Through long term contracts, the Company operates non-profit centers, returning all unused patient contributions, on a pro-rata basis to each co-op member in the form of additional product. In February 2010, Authoriszor Inc. completed the acquisition of GreenGro Technologies, Inc., and CannovaHealth, a clinic management company. In September 2011, the Company acquired Vertical Hydrogarden, Inc.

Medical marijuana (medical cannabis) is an alternative method to other forms of medication used to manage or alleviate pain without the undo side-effects caused by the prescription medication being used to treat an illness. The Company stands ready to assist in patient care co-operatives throughout the United States.

Advisors' Opinion:

• [By James E. Brumley]

  If it seems like the buzz surrounding marijuana stocks like Medical Marijuana Inc. (OTCMKTS:MJNA), Hemp, Inc. (OTCMKTS:HEMP), and GreenGro Technologies, Inc. (OTCMKTS:GRNH) has been a little louder than usual the last few days, you're not crazy - it has been louder, and particularly bullish. GRNH shares advanced 37% in December. HEMP is up 166% for the past two weeks. MJNA has jumped 47% in just the past couple of days. Well, as it turns out, it's not just mere coincidence that GreenGro Technologies, Hemp, Medical Marijuana, and a bunch of other cannabis-related names have perked up of late. And, odds are pretty good they'll all continue to do well (even of the pace slows a bit) in 2014.

• [By Dan Burrows]

  MediSwipe (MWIP) has tripled, with MWIP stock up 200%. Cannabis Science (CBIS) is closing in on quadrupling, as CBIS stock gained 273%. And GreenGro Technologies (GRNH)? Brace yourself, because GRNH stock is up over 1,000% … including an 18% so far today.

• [By Ben Levisohn]

  But, as the Huffington Post points out, most of the companies that stand to benefit are very small–they make micro caps look big–trade over the counter–good bye liquidity. That includes transaction-processing company MediSwipe (MWIPD), GreenGro Technologies (GRNH) Medbox (MDBX), which makes dispenser for high-risk drugs, and GW Pharmaceuticals (GWPRF).

• [By Dan Burrows]

  But it doesn’t end there. Investors should run away from all OTC marijuana stocks, including Medical Marijuana (MJNA), Cannabis Science (CBIS), CannaVest (CANV), MediSwipe (MWIP) and GreenGro Technologies (GRNH). As the SEC warns:

5 Best High Dividend Stocks To Own Right Now

Actionable Items:

Highest Positive Spread: ING Emerging Markets High Dividend Equity Fund (IHD)Focus Stock: Central Securities Corporation (CET)Last Week's Focus Stock: Central Securities Corporation

Junk Bonds Debacle: The $85 billion monthly bond-purchase program has produced a selloff for "junk" bonds. The U.S. Treasurys jumped 0.18% to 4.39% on Wednesday. The benchmark 10-Year Treasury note has risen 0.5% in the past month.

About $187 billion of junk bonds have been issued in the U.S. so far this year, a year-to-date record in data going back to 1995. This may be a sell-off of the "junk" bonds. The break in the pattern could mean high yield ("junk") investors may be threatened.

CEF "Junk" Bond Investors: Of the 73 CEFs of "HiYldBndFnds" it is only seven (7) CEFs without leverage. The leverage is 24% of net asset value, which will have to be leveraged again. Of "HiYldBndFnds" the premium is 0.9% and the average monthly yield is 7.2%. For the CEF industry (without HiYldBndFnds), the discount is -3.1% and the distribution yield is 6.0%.

Best Growth Stocks To Watch For 2015: Mitcham Industries Inc.(MIND)

Mitcham Industries, Inc., through its subsidiaries, engages in the leasing, sale, and service of geophysical and other equipment to the seismic industry worldwide. The company operates in two segments, Equipment Leasing and Seamap. The Equipment Leasing segment leases seismic equipment for short-term leasing primarily to seismic data acquisition contractors and oil field service providers. Its land equipment lease pool includes seismic recording land channels, geophones and cables, and other peripheral equipment; marine seismic equipment lease pool comprises streamers, air compressors, air guns, streamer positioning equipment, energy source controllers, and other equipment; and downhole equipment lease pool consist of downhole seismic tools. This segment is also involved in the sale of new seismic equipment of other manufacturers; heli-pickers and related equipment used in the deployment and retrieval of seismic equipment by helicopter; and equipment, consumables, systems integration, engineering hardware, and software maintenance support services to the seismic, hydrographic, oceanographic, environmental, and defense industries, as well as sells used equipment from its lease pool. The Seamap segment designs, manufactures, and sells a range of products for the marine seismic industry. Its products include GunLink seismic source acquisition and control systems, which are designed to provide operators of marine seismic surveys with precise control of energy sources; and BuoyLink RGPS tracking systems that are used to offer precise positioning of seismic sources and streamers. The company was founded in 1987 and is headquartered in Huntsville, Texas.

Advisors' Opinion:

• [By Dimitra DeFotis]

  The market seems to be showing fatigue particularly with positive onshore oil service data points that may no�longer seem incremental. Investors have become especially focused on potential issues and macro concerns. We believe this phase�of enhanced risk perceptions will pass and still recommend owning selective stocks based on attractive valuations and healthy�fundamentals. Of the 16 oilfield services companies having reported their quarters to date, the share price changes have at times�been difficult to tie to specific results. �… Five of the 12 companies who have beaten earnings expectations have seen their share prices drop on the day, including Basic Energy Services (BAS) (-9.0%), Baker Hughes (BHI) (-2.5%), National Oilwell Varco (NOV) (-1.5%), Oceaneering (OII) (-4.2%), and Schlumberger (SLB) (-2.0%). Other stocks beating expectations have traded higher as expected, including Cameron International (CAM) (+4.1%), FMC Technologies (FTI) (+3.1%), Mitcham Industries (MIND) (+3.8%), Nabors Industries (NBR) (+1.2%), Patterson-UTI Energy (PTEN) (+1.8%), RPC (RES) (+8.4%), and Weatherford International (WFT) (+2.3%). Companies which have missed have universally seen their share prices decline, including Diamond Offshore Drilling (DO) (-4.3%), Gulfmark Offshore (GLF) (-0.1%), and Hercules Offshore (HERO) (-6.9%). Halliburton (HAL) was in line and flat on the day.

5 Best High Dividend Stocks To Own Right Now: Glatfelter (GLT)

P. H. Glatfelter Company manufactures and sells specialty papers and fiber-based engineered materials in the United States and internationally. It offers carbonless and forms papers for credit card receipts, multi-part forms, security papers, and other end-user applications; book publishing papers for the production of hardbound books and other book publishing needs; envelope and converting papers for the direct mail market, shopping bags, and other converting applications; and engineered products for digital imaging, transfer, casting, release, postal, playing card, and other niche specialty applications. The company also provides food and beverage paper used for tea bags and single serve coffee products; metallized products used in the labeling of beer bottles, innerliners, gift wrap, self-adhesive labels, and other consumer products applications; and composite laminates papers used in production of decorative laminates, furniture, and flooring applications, as well as a line of paper products used in batteries, medical masks, and other engineered applications. In addition, it offers airlaid non-woven fabric-like materials used in feminine hygiene products, adult incontinence products, cleaning pads and wipes, food pads, napkins and tablecloths, and baby wipes. The company markets its products directly, as well as through wholesale paper merchants, brokers, and agents. P. H. Glatfelter Company was founded in 1864 and is headquartered in York, Pennsylvania.

Advisors' Opinion:

• [By Eric Volkman]

  Glatfelter (NYSE: GLT  ) has a new asset in its portfolio. The company announced it has finalized the acquisition of Germany-based Dresden Papier, which according to the American firm is "the leading global supplier of nonwoven wallpaper base materials."

• [By CRWE]

  Glatfelter (NYSE:GLT) reported that the previously announced presentation by Dante C. Parrini, Chairman and Chief Executive Officer, at the Deutsche Bank Global Industrials and Basic Materials Conference on Wednesday, June 13, 2012 will be available via a live web cast.

5 Best High Dividend Stocks To Own Right Now: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

• [By Jon C. Ogg]

  Pharmacyclics Inc. (NASDAQ: PCYC) was started as Overweight with a $142 price target at J.P. Morgan. Deutsche Bank also started it with a Buy rating and a $170 price target.

5 Best High Dividend Stocks To Own Right Now: Parametric Technology Corporation(PMTC)

Parametric Technology Corporation develops, markets, and supports product lifecycle management (PLM) software solutions and services that help companies design products, manage product information, and enhance product development processes worldwide. Its PLM solutions comprise Windchill, an Internet-based content and process management solution for managing data and relationships, processes, and publications; Arbortext, an enterprise solution to manage complex information assets that enhance their customer support and service center information delivery processes; Creo View, which enables enterprise-wide visualization, verification, annotation, and automated comparison of various product development data formats; and Integrity that coordinates and manages various activities and artifacts associated with developing software-intensive products. The company?s desktop solutions include Creo Parametric, a family of three-dimensional product design solutions based on a parametr ic, feature-based solid modeler that enables changes made during the design process to be associatively updated throughout the design; Creo Elements/Direct, a family of computer aided design and collaboration software used for customers to meet short design cycles and to create product designs; Mathcad, an engineering calculation software solution, which combines a computational engine, accessed through conventional math notation, and with a full-featured word processor and graphing tools; and Arbortext to help customers improve documentation accuracy, speed time to market, reduce translation requirements, and lower publishing costs. In addition, it provides consulting, implementation, training, maintenance, and computer-based training products. Parametric Technology sells its products and services through direct sales force and third-party resellers and other strategic partners. The company was founded in 1985 and is headquartered in Needham, Massachusetts.

Advisors' Opinion:

• [By Northrop Puckett]

  The company is facing headwinds in the broader economy. This can be seen in declining sales in many areas of their business. Regionally, the U.S was flat; Northern Europe was up; Southern Europe was down; and emerging markets were down. Autodesk also lowered quarterly and yearly revenue expectations. This lowering of guidance by Autodesk also matches the same guidance changes made by competitors Parametric Technology (PMTC) and ANSYS (ANSS), so it is not necessarily losing out to its rivals in this case.